Why It Matters
By focusing on protein surface geometry, Immuto’s technology could transform how we develop safer, more effective drugs for cancers and other diseases where traditional targets are shared with normal cells. This breakthrough addresses a critical bottleneck in precision medicine, offering hope for patients who currently lack viable treatment options.
Key Takeaways
- •Toxicity causes one‑third of clinical trial failures.
- •Disease‑specific protein conformations create novel druggable epitopes.
- •Immuto’s AI‑driven structural surfenomics maps protein shapes in cells.
- •Platform achieves >1,000‑fold selectivity, widening therapeutic windows.
- •Approach accelerates target validation and may rescue previously failed drugs.
Pulse Analysis
Toxicity remains a leading cause of drug attrition, accounting for roughly one‑third of clinical failures, especially in oncology where narrow therapeutic windows limit dosing. Conventional target selection relies on protein sequence alone, leading to off‑target effects that damage healthy tissue and force dose reductions. By focusing on disease‑specific protein conformations—structural signatures that emerge from the stressed tumor microenvironment—researchers can differentiate malignant cells from normal ones, unlocking previously hidden epitopes and expanding the pool of viable targets.
Immuto Scientific’s AI‑enabled structural surfenomics platform tackles this challenge by integrating high‑throughput proteomics with in‑situ structural analysis. The system captures thousands of protein shapes directly from patient‑derived disease models, then employs generative deep‑learning models to pinpoint disease‑specific conformations. Ranked by structural change, stability, membrane presence, and literature relevance, these targets feed into an AI‑driven antibody design stack that engineers binders at the residue level. The resulting therapeutics—ranging from antibody‑drug conjugates to bispecifics—exhibit selectivity ratios exceeding 1,000‑to‑1, dramatically widening therapeutic windows and reducing toxicity.
Beyond improving safety, Immuto’s workflow promises substantial cost and timeline savings by front‑loading target validation. Early identification of disease‑exclusive epitopes can rescue programs previously abandoned for toxicity, while the ability to map conformational pockets on traditionally “undruggable” proteins opens new therapeutic avenues across oncology, immunology, and inflammation. By marrying structural proteomics with AI, the platform not only mitigates clinical trial attrition but also broadens the druggable genome, offering a compelling economic case for investors and a hopeful path for patients awaiting more precise treatments.
Episode Description
Finding New Targets on the Surface of Misfolded
One of the biggest hurdles in drug development is targeting proteins found in both healthy and diseased cells without triggering toxic side effects. In cancer, this challenge often translates into narrow therapeutic windows, collateral damage to normal tissues, and forced dose reductions that limit efficacy. The result is a crowded field where many companies chase the same well-known targets, leaving vast patient populations without effective options. Immuto Scientific is taking a different approach. The company is redefining how targets are identified—focusing not on genetic sequence, but on disease-specific protein conformations. By studying the structural shapes that proteins take in malignant cells, Immuto aims to distinguish cancerous from healthy tissue, broaden therapeutic windows, and unlock new or previously undruggable targets across oncology and beyond. We spoke with Faraz Choudhury, co-founder and CEO of Immuto Scientific, about the company’s AI-enabled structural surfaceomics platform, how it allows drugs to selectively home in on diseased cells while sparing normal ones, and Immuto’s plans to extend its science into immunology and inflammation.
Proteins
Show Notes
0
Comments
Want to join the conversation?
Loading comments...